Sfoglia per Autore
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells
2001-01-01 We, Carson; R, Parihar; Mj, Lindemann; Personeni, N.; J, Dierksheide; Nj, Meropol; J, Baselga; Ma, Caligiuri
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
2003-01-01 Bozzetti, C.; Personeni, N.; Nizzoli, R.; Guazzi, A.; Flora, M.; Bassano, C.; Negri, F.; Martella, E.; Naldi, N.; Franciosi, V.; Cascinu, S.
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer
2005-01-01 Personeni, N.; Hendlisz, A.; Gallez, A.; Gomez Galdon, M.; Larsimont, D.; Van Laethem, Ji.; Nagy, N.; Barette, M.; Paesmans, M.; Cardoso, F.; Bleiberg, H.
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes
2006-01-01 A, Hendlisz; Personeni, N.; T, Delaunoit; S, Debroux; P., Flamen
Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib : does intratumoral heterogeneity matter?
2006-01-01 Personeni, N.
Response prediction to EGFR-targeted therapies in colorectal cancer
2006-01-01 Personeni, N.; S, Tejpar; E., Van Cutsem
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas : can we improve epidermal growth factor receptor and phospho-AKT testing?
2007-01-01 Personeni, N.
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer
2007-01-01 M, Colozza; E, Azambuja; Personeni, N.; F, Lebrun; Mj, Piccart; F., Cardoso
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas : can we improve epidermal growth factor receptor and phospho-AKT testing?
2007-01-01 Personeni, N.
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
2008-01-01 W, De Roock; H, Piessevaux; J, De Schutter; M, Janssens; G, De Hertogh; Personeni, N.; B, Biesmans; Laethem Jl, Van; M, Peeters; Y, Humblet; E, Van Cutsem; S., Tejpar
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study
2008-01-01 Personeni, N.; Fieuws, S.; Piessevaux, H.; De Hertogh, G.; De Schutter, J.; Biesmans, B.; De Roock, W.; Capoen, A.; Debiec Rychter, M.; Van Laethem, J.; Peeters, M.; Humblet, Y.; Van Cutsem, E.; Tejpar, S.
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study
2008-01-01 Personeni, N.; Fieuws, S.; Piessevaux, H.; De Hertogh, G.; De Schutter, J.; Biesmans, B.; De Roock, W.; Capoen, A.; Debiec Rychter, M.; Van Laethem, J.; Peeters, M.; Humblet, Y.; Van Cutsem, E.; Tejpar, S.
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
2008-01-01 W, De Roock; H, Piessevaux; J, De Schutter; M, Janssens; G, De Hertogh; Personeni, N.; B, Biesmans; Laethem Jl, Van; M, Peeters; Y, Humblet; E, Van Cutsem; S., Tejpar
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
2010-01-01 Santoro, A; Pressiani, T; Citterio, G; Rossoni, G; Donadoni, G; Pozzi, F; Rimassa, L; Personeni, N; Bozzarelli, S; Rossoni, G; Colombi, S; De Braud, Fg; Caligaris-Cappio, F; Lambiase, A; Bordignon, C
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
2010-01-01 Santoro, A.; Pressiani, T.; Citterio, G.; Rossoni, G.; Donadoni, G.; Pozzi, F.; Rimassa, L.; Personeni, N.; Bozzarelli, S.; Rossoni, G.; Colombi, S.; De Braud, F. G.; Caligaris Cappio, F.; Lambiase, A.; Bordignon, C.
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy
2010-01-01 Hendlisz, A.; Van Den Eynde, M.; Peeters, M.; Maleux, G.; Lambert, B.; Vannoote, J.; De Keukeleire, K.; Verslype, C.; Defreyne, L.; Van Cutsem, E.; Delatte, P.; Delaunoit, T.; Personeni, N.; Paesmans, M.; Van Laethem, J.; Flamen, P.
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough?
2011-01-01 Personeni, N.; Torzilli, G.; Santoro, A.
Fatal Infusion Reaction to Cetuximab : The Need for Predictive Risk Factors and Safer Patient Selection
2011-01-01 Tronconi, M. C.; Sclafani, F.; Rimassa, L.; Carnaghi, C.; Personeni, N.; Santoro, A.
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection
2011-01-01 Tronconi, Mc; Sclafani, F; Rimassa, L; Carnaghi, C; Personeni, N; Santoro, A
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough?
2011-01-01 Personeni, N.; Torzilli, G.; Santoro, A.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile